

Research Paper

20-HETE mediated TRPV1 activation drives allokinesia via MrgprA3⁺ neurons in chronic dermatitis

Guang Yu^{1,2*}✉, Pei Liu^{1*}, Xiaobao Huang^{3*}, Mingxin Qi², Xue Li², Weimeng Feng¹, Erxin Shang¹, Yuan Zhou², Changming Wang², Yan Yang², Chan Zhu², Fang Wang³, Zongxiang Tang²✉, Jinao Duan¹✉

1. Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing, China.
2. Key Laboratory for Chinese Medicine of Prevention and Treatment in Neurological Diseases, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
3. Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

* Guang Yu, Pei Liu and Xiaobao Huang are co-first authors.

✉ Corresponding author: Guang Yu, E-mail: yuguang@njucm.edu.cn; Zongxiang Tang, E-mail: tangzlab@njucm.edu.cn; Jinao Duan, E-mail: dja@njucm.edu.cn (J.D.).

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2023.04.12; Accepted: 2024.01.26; Published: 2024.02.04

Abstract

Rationale: Noxious stimuli are often perceived as itchy in patients with chronic dermatitis (CD); however, itch and pain mechanisms of CD are not known.

Methods: TRPV1 involvement in CD was analyzed using a SADBE induced CD-like mouse model, and several loss- and gain-of-function mouse models. Trigeminal TRPV1 channel and MrgprA3⁺ neuron functions were analyzed by calcium imaging and whole-cell patch-clamp recordings. Lesional CD-like skin from mice were analyzed by unbiased metabolomic analysis. 20-HETE availability in human and mouse skin were determined by LC/MS and ELISA. And finally, HET0016, a selective 20-HETE synthase inhibitor, was used to evaluate if blocking skin TRPV1 activation alleviates CD-associated chronic itch or pain.

Results: While normally a pain inducing chemical, capsaicin induced both itch and pain in mice with CD condition. DREADD silencing of MrgprA3⁺ primary sensory neurons in these mice selectively decreased capsaicin induced scratching, but not pain-related wiping behavior. In the mice with CD condition, MrgprA3⁺ neurons showed elevated ERK phosphorylation. Further experiments showed that MrgprA3⁺ neurons from *MrgprA3;Braf* mice, which have constitutively active BRAF in MrgprA3⁺ neurons, were significantly more excitable and responded more strongly to capsaicin. Importantly, capsaicin induced both itch and pain in *MrgprA3;Braf* mice in an MrgprA3⁺ neuron dependent manner. Finally, the arachidonic acid metabolite 20-HETE, which can activate TRPV1, was significantly elevated in the lesional skin of mice and patients with CD. Treatment with the selective 20-HETE synthase inhibitor HET0016 alleviated itch in mice with CD condition.

Conclusion: Our results demonstrate that 20-HETE activates TRPV1 channels on sensitized MrgprA3⁺ neurons, and induces allokinesia in lesional CD skin. Blockade of 20-HETE synthesis or silencing of TRPV1-MrgprA3⁺ neuron signaling offers promising therapeutic strategies for alleviating CD-associated chronic itch.

Keywords: 20-HETE, TRPV1, allokinesia, MrgprA3⁺ neurons, chronic dermatitis

Introduction

Pain and itch are unpleasant sensations with cognitive, discriminatory, affective, and motivational components. These distinct somatosensory modalities elicit distinct behavioral responses, and are

antagonistic - i.e. pain can inhibit itch [1, 2]. Recent progress suggests that itch and pain are encoded and transmitted by discrete groups of primary sensory neurons (pruriceptive neurons and nociceptive

neurons, respectively) in the trigeminal ganglia (TG) and dorsal root ganglia (DRG) [1, 2]. However, the boundary between pain and itch becomes blurred in pathological conditions. For instance, iontophoresis of itch-inducing histamine is perceived as painful in patients with chronic pain [3, 4], while noxious mechanical, thermal and chemical stimuli are perceived as itchy in patients with chronic itch [5-7]. The central or peripheral mechanisms of sensory switching is not known. It has been assumed that chronic itch leads to central sensitization of spinal itch circuits, so that inputs from peripheral nociceptive neurons are perceived as itchy rather than painful [6, 7]. However, this theory is complicated by the discovery that most noxious stimuli, including capsaicin, activates pruriceptive neurons in addition to nociceptive neurons - suggesting that pain detection in the periphery stimuli also involve itch components [8-10].

Previous studies have identified several itch receptors among the Mas-related G protein-coupled receptors (Mrgprs) family, which includes more than 50 members in mice [8, 11, 12]. Most Mrgprs are expressed solely by primary sensory neurons in the TG and DRG. MrgprA3 was identified as a receptor for chloroquine (CQ), an anti-malarial drug with serious pruritic side effects, and mediates histamine-independent itch induced by CQ [8]. Interestingly, MrgprA3 is expressed by a highly restricted population of primary sensory neurons that accounts for about 5% of total DRG neurons [8]. In addition to MrgprA3, this population also expresses high levels of histamine H1 receptors, serotonin receptors, proteinase activated receptors, as well as other Mrgprs, and can be activated by a variety of pruritogens. MrgprA3⁺ neurons selectively innervate skin in mice, and genetic ablation of this population results in severe defects in both acute and chronic itch. Conversely, specific activation of this population elicits robust itch-related scratching behavior. Together, these results indicate that MrgprA3⁺ neurons are itch selective primary sensory neurons [8, 11]. Indeed, a recent study demonstrated that selective activation of these pruriceptive neurons using capsaicin, in the absence of nociceptive neurons activation, elicits itch [13].

Based on these previous reports, we hypothesized that selective sensitization of pruriceptive neurons occurs during chronic dermatitis (CD) condition, and hypersensitivity of itch sensing neurons suppress pain pathways. It is possible that the antagonistic relationship between pain and itch is bidirectional, depending on the relative activity of pain and itch pathways. However, it is unclear if or how MrgprA3⁺ neurons mediate itch and pain in

chronic itch as hypothesized above. In this study, we examined the role of MrgprA3⁺ neurons under chronic itch conditions. Our results advance the understanding of abnormal sensory coding and dysregulated pain and itch crosstalk that occurs in CD condition, as well as provides critical information and therapeutic targets for itch management.

Materials and methods

Skin donors

Punch biopsies were obtained from healthy human skin and lesional skin of patients with CD, all of whom had active disease and did not receive any topical or systemic therapy for two or four weeks, respectively, before biopsy. Informed consent was obtained from all donors prior to biopsy and all procedures were approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (IRB number 2023 [068]).

Animals

C57BL/6J mice, *Mrgpra3^{Cre-Gfp+}* (*MrgprA3- Cre*, heterozygous for MrgprA3) mice, *Mrgpr-clusterΔ^{-/-}* (*Mrgprs^{-/-}*) mice, *B-raf^{V600E}* mice (*Braf* mice), *Rosa26^{tdTomato}* (*tdTomato*) mice and their WT littermate mice were used. Animals were bred as appropriate to generate: 1. *MrgprA3;Braf* mice, in which the constitutively active B-raf^{V600E} allele is specifically expressed in MrgprA3⁺ neurons; 2. *MrgprA3;tdTomato* reporter mice, in which the tdTomato fluorescent reporter is specifically expressed in MrgprA3⁺ neurons and nerve fibers; and 3. *MrgprA3;Braf;tdTomato* mice, in which both the constitutively active B-raf^{V600E} allele and the tdTomato fluorescent reporter are specifically expressed in MrgprA3⁺ neurons and nerve fibers.

Animal experiments were conducted in accordance with the relevant guidelines and regulations of the Institutional Animal Care and Use Committee of Nanjing University of Chinese Medicine (ACU190601). All mice used in this study were housed and tested in controlled environments with 20-24°C, 45-65% humidity, and 12-hour day/night light cycle. 8 to 10 week old male mice were used for behavioral tests, and littermate controls were used if possible. For our current study, we also generated the nape CD model using female mice to compare the sex-related differences on behavior. Researchers were blinded to animal genotypes and experimental groups throughout all manipulations, treatments, and data quantification.

Generation of mouse CD model

CD model was induced using squaric acid dibutylester (SADBE) as reported previously [14].

Briefly, mice were sensitized by topical application of 25 μ L 1% SADBE in acetone onto their shaved abdominal skin once daily, starting on Day 1, for three consecutive days. Mice in the control group were treated with an acetone vehicle. Starting on Day 9, mice were challenged with topical application of 25 μ L 0.5% SADBE in acetone onto their shaved nape or cheek skin once daily for five or three consecutive days. Control mice were challenged with acetone vehicle. Twenty-four hours after the challenge, scratching and wiping directed at the treated area were filmed and counted using criteria defined by our previous studies and relevant publications [15].

Behavioral assay

Animals were acclimated to the testing environment for 15 minutes before the start of behavior tests. Scratching behavior in CD model animals were analyzed for 30 min immediately after habituation. Scratching behavior induced by subcutaneously injected CQ or capsaicin were observed for 30 min immediately after injection. A bout of scratching was defined as a continuous scratching movement with a hindlimb directed at the treatment or injection site, only those unilateral wipes with the forelimb directed at the treatment or injection site were defined as a continuous wiping movement [16]. Drugs were administered as indicated in the figures, usually 24 hours after the third SADBE challenge. Drug dosages were selected based on pilot experiments or our previous studies or relevant studies [15], and are as follows: capsaicin (cheek, 500 μ M, 20 μ L; Sigma), chloroquine (cheek, 2 mM, 20 μ L; Sigma), HET0016 (intraperitoneal, 2 mg/kg; Glpbio).

DREADD studies

To genetically silence *MrgprA3* neurons using the inhibitory, Gi-coupled hM4Di DREADD (designer receptors exclusively activated by designer drugs) receptor, hM4Di-mCherry adeno-associated virus (AAV) (Genomeditech, China) was injected by tail vein (10^{11} VG in 100 μ L) into hemizygous *MrgprA3-Cre* and *MrgprA3;Braf* mice three weeks before the start of behavior experiments. 30 minutes after i.p. clozapine-N-oxide (CNO) injection (5 mg/mL, 100 μ L/mouse), *MrgprA3*⁺ neurons are silenced and further capsaicin treatments only activate TRPV1⁺/*MrgprA3*⁺ neurons.

TG neuron culture

TGs were dissected and collected in cold DH10 medium (90% DMEM/F-12, 10% FBS, 100 U/ml penicillin, 100 μ g/ml streptomycin, Gibco) and digested with enzyme based dissociation solution (1 mg/mL Collagenase Type I and 5mg/mL Dispase in

HBSS without Ca²⁺ and Mg²⁺, Gibco) at 37°C for 25-30 min with intermittent agitation. TG neurons were then freed by trituration through a pipette and large debris were removed using a cell strainer. Afterwards, neurons were pelleted by centrifugation, media was removed, and cells were re-suspended in warm (37°C) DH10 medium supplemented with nerve growth factor (NGF, 20 ng/ml) and glial cell line-derived neuro-trophic factor (GDNF) (25 ng/mL). Neurons were then seeded onto poly-D-lysine (0.5 mg/mL) and laminin (10 μ g/mL) coated glass coverslips, cultured in an incubator (95% O₂ and 5% CO₂) at 37°C, and used within 24 hours.

Ca²⁺ imaging

Calcium imaging was performed as previously described [17]. In brief, cultured TG neurons were loaded with Fura-2 acetoxymethyl ester (Molecular Probes) for 30 min at room temperature. After washing and recovery for 5 min, cells were imaged at 340 and 380 nm excitation to detect free intracellular calcium. Neurons were considered responsive if $\geq 50\%$ increase in baseline 340/380 fluorescence ratio was observed after stimulus administration. In Figure S3, TG neurons were loaded with Fluo-4 acetoxymethyl ester, neurons were imaged at 488-nm excitation to detect intracellular Ca²⁺ transients. In Figure S10, GFP signals from PirtGCaMP3-cultured neurons were imaged at 488-nm excitation to detect intracellular Ca²⁺ transients.

Whole-cell patch-clamp recordings

MrgprA3⁺ neurons from *MrgprA3;tdTomato* and *MrgprA3;Braf; tdTomato* mice were first identified by red tdTomato fluorescence using wide field microscopy (ZEISS, Axio Observer D1, Germany) and marked manually. Afterwards, coverslips were transferred into the electrophysiology recording chamber with extracellular solution. Whole-cell current clamp and voltage-clamp recording experiments were performed at room temperature (23 - 25°C) using a multi-clamp 700B amplifier and digital 1440 with pClamp10 software (Molecular Devices, USA) as previously described [17]. Signals were sampled at 20 kHz and filtered at 2 kHz. Patch pipettes were pulled from borosilicate glass capillaries using a P-97 micropipette puller (Sutter Instrument) and all had resistances between 3 - 4 M Ω . Series resistance was routinely compensated at 60 - 80%. Resting membrane potential (RMP) was recorded for each neuron under the current-clamp mode after stabilization (within 3 min). Neurons with seal resistance below 1 G Ω were excluded from analysis. The liquid junction potential is 8 mV and corrected. To test AP firing, each neuron was injected with a

series of depolarizing currents, 200ms duration and in 20 pA increments. Current threshold was defined as the minimum current required to induce an AP. Other AP-related parameters were measured in Clampfit software. Internal solution (in mM): KCl 135, MgATP 3, Na₂ATP 0.5, CaCl₂ 1.1, EGTA 2, Glucose 5, adjusted to pH 7.38 using KOH and 300 mOsm with sucrose. External solution (in mM): NaCl 140, KCl 4, CaCl₂ 2, MgCl₂ 2, HEPES 10, Glucose 5, adjusted to pH 7.4 using NaOH and 310 mOsm with sucrose.

Western blot

Western blotting was performed as described previously [17]. Briefly, fresh tissues were homogenized in RIPA buffer (P0013B, Beyotime, China) in accordance with the manufacturer's protocols. Protein concentration was determined by BCA assay. 60 µg of protein was loaded per lane and resolved on 12% SDS-polyacrylamide gels. Polyclonal anti-pERK antibody (#4370, Cell signaling technology) and monoclonal GAPDH antibody (ab8245, Abcam) were both used at 1:1000 dilution. Primary antibodies were detected using HRP-conjugated goat anti-rabbit antibodies and a chemiluminescence kit (Tanon, Shanghai, China). Band intensities were quantified using ImageJ software.

Untargeted metabolomics analyses

Total protein lysate from skin were prepared using RIPA Lysis Buffer and protein concentration was determined by BCA assay. Samples were desalted using Ziptip C18 columns before LC-MS analysis. UPLC-Q-TOF/MS analysis was performed using an UHPLC Acquity™ system (Waters Corp., Milford, MA, USA) coupled to a Synapt™ Q-TOF mass spectrometer with electrospray ionization (ESI) in positive and negative modes. Phase separation was performed on an ACQUITY UPLC BEH-C18 chromatographic column (2.1 × 100 mm, 1.7 µm) at 30°C. 2 µL of each sample was injected and flow rate of the mobile phase was set to 0.4 mL/min. Acetonitrile (ACN) gradient was increased stepwise from 0% with 0.1% formic acid to 95% over 20 minutes as follows: 0–2.5 min, 5–35 % ACN; 2.5–4 min, 35–45 % ACN; 4–10 min, 45–65 % ACN; 10–11 min, 65–85 % ACN; 11–16 min, 85–90% ACN; 16–18 min, 90–95% ACN; 18–19 min, 95% ACN; 19–19.5 min, 95–5% ACN; 19.5–20 min, 5% ACN.

To maximize metabolite identification, mass data were acquired for m/z 100 to 1000 in both the negative and positive ESI modes. Data were acquired using the MSE method using low (6 eV) and high (20–60 eV) energy functions for precursor and fragments, respectively. Calibration was performed

using leucine-enkephalin (ESI⁺: m/z 556.2771, ESI⁻: m/z 554.2615). Optimizations include: 140°C ion source temperature, 800 L/h 400°C nitrogen desolvation gas, 50 L/h cone gas, 0.15 mL/min collision gas, 3 kV capillary voltage in the positive mode and 2.5 kV in the negative mode, 30 V cone voltage, 1 V ion guide, and 40 psi nebulizer pressure.

Raw data were processed using MassLynx™ v4.1 workstation software (Waters Corp.) for metabolic fingerprint profiling including peak detection, noise removal, filtering, and alignment. Processed data matrix includes retention time (tR), m/z value, and normalized ion intensity for each peak area.

Endogenous metabolites with variable projection importance (VIP) value in OPLS-DA greater than 1 and t-test *P* value < 0.05 were considered differential metabolites associated with CD. The differential metabolites were identified by combining and comparing with Human Metabolome Database (HMDB: <https://hmdb.ca/>) and other databases. These metabolites were introduced into Metaboanalyst 5.0 for analyzing their related metabolic pathways (<https://www.metaboanalyst.ca/>) [18]. Impact values present the topology structure's importance of metabolites in their corresponding metabolic pathways. The higher the impact value, the greater the structure's importance of metabolites involved in this pathway [19].

20-HETE assay

The UHPLC analysis was performed using a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, USA). Separation was performed using an Acquity UPLC CSH-C18 column (2.1 mm × 100 mm, 1.7 µm, Waters, Milford, USA). 2 µL of each sample was injected and flow rate of the mobile phase was set to 0.4 mL/min. Linear gradient elution was performed with 0.1% formic acid / water (v/v, solvent A) and acetonitrile (solvent B), and separation was carried out over 30 min with gradually increasing ACN: 0–7min, 5%–10% ACN; 7–10 min, 10%–20% ACN; 10–12 min, 20% ACN; 12–14 min, 20%–45% ACN; 14–21min, 45%–80% ACN; 21–27 min, 80%–100% ACN; 27–28.5 min, 100%–5% ACN; 28.5–30 min, 5%. Column temperature was maintained at 30°C. Mass spectra was acquired for m/z 100 to 1000 Da in centroid mode using an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific, USA) with ESI, and processed using Xcalibur™ v2.2 (Thermo Scientific, USA). Optimizations include: 3.8 kV spray voltage, > 99.99% pure nitrogen sheath gas and auxiliary gas, > 99.99% pure helium collision gas, sheath gas flow rate 25 AU, auxiliary gas flow rate 15 AU, 350°C ion source temperature, 320°C capillary temperature.

20-HETE concentration in skin lysates of HET0016 treated mice were measured by 20-HETE enzyme-linked immunosorbent assay (ELISA) kit (mlbio, Shanghai, China) according to the manufacturer's instruction.

Immunofluorescence

Immunofluorescent imaging of TG and skin tissue were performed as previously described [20]. Briefly, mice were anesthetized with 1% sodium pentobarbital (50 mg/kg, i.p.) and transcardially perfused with cold 0.1 M phosphate-buffered saline (PBS, pH 7.4, 4°C) followed by 4% paraformaldehyde in PBS (pH 7.4, 4°C). TG and skin were then dissected and cryoprotected in 30% sucrose at 4°C for 24 hours. Afterwards, dissected tissues were embedded in optimum cutting temperature compound (OCT, Leica, Wetzlar, Germany) and rapidly frozen at -20°C (CM1950, Leica). TGs and skin were sectioned at 10 µm or 50 µm thickness, respectively, and slide mounted using a sliding microtome (CM1950, Leica). Slides were then incubated in blocking solution (10% fetal bovine serum in PBS containing 0.1% Triton X-100) for 30 min at room temperature, followed by primary antibody at 4°C overnight and in secondary antibody at room temperature for 2 hours in the dark. Images were acquired using an Olympus fluorescence microscope (BX51, Olympus Japan).

Data analysis

All experiments were performed by researchers blinded to animal genotype or experimental group. Experimental groups, treatment order, and testing order were assigned using simple randomization. Data are presented as the mean ± SEM. Data analysis was performed using GraphPad Prism 8.0 software (GraphPad Software Inc., San Diego, CA, USA). For statistical comparisons between 2 groups, either unpaired Student's t test (2-tailed) or Mann-Whitney U test with Welch's correction was used, depending on normality of data distribution. One-way analysis of variance (ANOVA) was used for the comparisons among multiple groups. Difference was considered statistically significant if $P < 0.05$.

Results

TRPV1 mediated itch is selectively enhanced in the SADBE-induced CD model mouse

Squaric acid dibutylester (SADBE), a small molecule hapten, has commonly been used to induce non-allergic and allergic CD in mice and, in a similar fashion, an area of contact hypersensitivity (CHS). Similar to previous reports [14], our SADBE nape model induced significant spontaneous scratching behavior in mice (Figure S1A-B). To examine the effect

of this model on pain and itch sensation, we further tested the acute effects of CQ or capsaicin 24 hours after two challenges (Figure S1C). Both CQ and capsaicin induced significant scratching response in mice (Figure S1D). Moreover, compare to vehicle control treated mice, scratching responses to both CQ (50 ± 11 SADBE vs. 24 ± 3.6 Control) and capsaicin (64 ± 10.5 SADBE vs. 28 ± 6.6 control) were enhanced in CD mice (Figure S1E). The enhanced scratching behavior induced by capsaicin was also observed in CD female mice (Figure S1F).

To further validate the pain and itch effects of CQ or capsaicin in CD, we generated a cheek model where pain and itch behavioral responses can be differentiated by forelimb wiping (pain) or hindlimb scratching (itch) (Figure S2A) [16]. In this model, SADBE treatment induced both scratching (21 ± 3.8 SABDE vs. 2.6 ± 0.9 Control) and wiping behavior (54 ± 6.3 SADBE vs. 18 ± 2.7 Control) in mice after 3 challenges (Figure 1A-B). CQ injection specifically increased scratching, but not wiping, behavior in both control and CD model mice (Figure 1C and F). Moreover, compared to control mice, CQ induced scratching was especially enhanced in CD model mice (68 ± 8.9 SADBE vs. 43 ± 5.7 Control) (Figure 1E), while no difference in wiping responses was detected (Figure 1D). This finding is consistent with common reports of hyperkinesis in chronic itch patients [21]. Vehicle injection did not produce any detectable effects on scratching or wiping behavior in CD model mice (Figure S2B). Interestingly, change in capsaicin induced wiping behavior was not significantly different between control and CD model mice (48 ± 16.5 SADBE vs. 30 ± 4.2 Control) (Figure 1C, G), but capsaicin only induced scratching in CD mice (20 ± 1.8 SADBE vs. 4 ± 2.4 Control) (Figure 1F, H). This observation is consistent with previous reports, that chronic itch enhanced excitability of nociceptors [15, 22].

MrgprA3⁺ neurons are required for TRPV1 mediated itch in CD condition

Although TRPV1 was reported to contribute to MrgprA3⁺ mediated itch sensations [13], the involvement Mrgprs (including MrgprA3) in capsaicin induced itch and pain in CD disorder has not been tested. To examine this possibility, we generated the CD model using *Mrgprs*^{-/-} mice. Mrgprs deficiency resulted in significantly decreased scratching behavior in the CD model (10 ± 1.6 *Mrgprs*^{-/-} mice vs. 21 ± 3.8 WT) (Figure 2A) without affecting pain related wiping behavior (Figure 2C). Moreover, CQ injection enhanced scratching in WT, but not *Mrgprs*^{-/-} CD model mice (Figure 2A), without effects in wiping behavior (Figure 2C). Remarkably,

capsaicin enhancement of wiping and scratching were similar in WT and *Mrgpr3^{-/-}* CD model mice (Figure 2A-D), suggesting that *Mrgpr3* are not required for capsaicin induced pain or itch in the CD model mice.

To further test if *MrgprA3⁺* neurons are required for itch and pain in the mouse CD model, we examined the effects of DREADD mediated genetic silencing of *MrgprA3⁺* neurons. To accomplish this, we specifically introduced the inhibitory Gi-coupled hM4Di receptor into *MrgprA3⁺* neurons using AAV and *MrgprA3-Cre* mice. CQ induced calcium response in cultured TG neurons was significantly decreased in the hM4Di group after CNO pretreatment (Figure S3 A-B). CQ induced scratching behavior was significantly decreased in the hM4Di group after i.p.

CNO pretreatment (Figure S3 C), without detectible differences in either CQ or capsaicin induced wiping (Figure S3 D). Moreover, CNO specifically inhibited CD-associated spontaneous scratching in the hM4Di group (Figure 2E, left panel) without effects on spontaneous CD-associated wiping (Figure 2F, left panel). Importantly, in the CD model mice, only capsaicin induced scratching (Figure 2E, right panel), but not wiping (Figure 2F, right panel), was significantly inhibited by CNO pretreatment. Together, our results demonstrate that while *Mrgpr3* are required for CD-associated chronic itch, *MrgprA3⁺* neurons, but not *Mrgpr* receptors, are required for capsaicin induced allodynia in SADBE model.




Figure 1. TRPV1 mediated itch is selectively enhanced in the SADBE-induced CD mouse model. (A) Schematic of the SADBE induced CD model and time points of drug injections. **(B)** Spontaneous wiping and scratching behavior in vehicle treated control and SADBE treated CD model mice. (n = 6). **(C)** Capsaicin (500 μ M/20 μ L) or CQ (2 mM/20 μ L) induced wiping in control and CD model mice. (n = 6). **(D)** The change in wiping response after CQ injection in control mice (the number of CQ-induced wiping in control group - the number of vehicle-induced wiping in control group) and CD model mice (the number of CQ-induced wiping in SADBE model group - the number of vehicle-induced wiping in SADBE model group). **(E)** The change in scratching after CQ injection in control mice (the number of CQ-induced scratching in control group - the number of vehicle-induced scratching in control group) and CD model mice (the number of CQ-induced scratching in SADBE model group - the number of vehicle-induced

scratching in SADBE model group). (F) Capsaicin (500 $\mu\text{M}/20 \mu\text{L}$) or CQ (2 mM/20 μL) induced scratching behavior in control and CD model mice. (n = 6). (G) The change in wiping response after capsaicin injection in control mice (the number of capsaicin-induced wiping in control group - the number of vehicle-induced wiping in control group) and CD model mice (the number of capsaicin-induced wiping in SADBE model group - the number of vehicle-induced wiping in SADBE model group). (H) The change in scratching after capsaicin injection in control mice (the number of capsaicin-induced scratching in control group - the number of vehicle-induced scratching in control group) and CD model mice (the number of capsaicin-induced scratching in SADBE model group - the number of vehicle-induced scratching in SADBE model group). (n = 6). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. All data are presented as mean \pm SEM.




Figure 2. *MrgprA3*⁺ neurons are required for TRPV1 mediated itch in CD condition. (A) Capsaicin (500 $\mu\text{M}/20 \mu\text{L}$) or CQ (2 mM/20 μL) induced scratching behavior in WT and *Mrgpr3*^{-/-} mice with CD condition. (n = 6). (B) The change in scratching after capsaicin injection in WT and *Mrgpr3*^{-/-} mice with CD condition. (C) Capsaicin (500 $\mu\text{M}/20 \mu\text{L}$) or CQ (2 mM/20 μL) induced wiping behavior in WT and *Mrgpr3*^{-/-} mice with CD condition. (n = 6). (D) The change in wiping after capsaicin injection in WT and *Mrgpr3*^{-/-} mice with CD condition. (E-F) Spontaneous and capsaicin induced scratching (E) and wiping (F) behavior in CNO treated (30 min pre) control and *MrgprA3*-hM4Di mice with CD condition. The changed behavior analysis method is consistent with Figure 1. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. All data are presented as mean \pm SEM.

ERK phosphorylation is enhanced in *MrgprA3*⁺ neurons in CD condition

Raf/MEK/ERK (MAPK) signaling regulates the expression and activity of a plethora of transcription factors and exerts actions across a wide array of cellular functions. One previous study had reported that U0126, a MEK inhibitor, attenuated scratching in a chronic itch model [23]. To study if MAPK elevated ERK phosphorylation signaling contributes to *MrgprA3*⁺ neuron mediated in CD-like disease, we examined activated ERK (pERK) in *MrgprA3*⁺ TG neurons of CD model mice (Figure 3A). After the third SADBE challenge, the percentage of pERK⁺ neurons in the TG was increased from 8.5 ± 0.6 (control) to 19.0 ± 1.5 (CD model) (Figure 3B). Importantly, the percentage of pERK and *MrgprA3* double-positive neurons was significantly increased in CD model mice (12.9 ± 1.6 control vs. 70.5 ± 4.6 CD model mice) (Figure 3C). In addition to pERK, nerve fiber density in the skin is often increased in chronic itch skin condition, which may also contribute to enhanced itch and itch detection. To test if this is another parallel mechanism of CD-associated itch, the length of

MrgprA3⁺ sensory fibers per square millimeter was measured in skin of control and CD model mice. Indeed, the density of *MrgprA3*⁺ fiber in skin was significantly increased (Figure 3D-E).

ERK phosphorylation is enhanced in *MrgprA3*;Braf mice

BRAF is a serine/threonine kinase that activates ERK, a member of the MAPKs superfamily, through the RAF/MEK/ERK cascade [24]. To mimic the increased ERK phosphorylation and excitability of *MrgprA3*⁺ neurons in our CD model, and to investigate *MrgprA3*⁺ neuron functions in itch and pain, we crossed *MrgprA3-Cre* mice with *Braf* mice. In the resulting *MrgprA3*;Braf mice, constitutively active Braf is specifically expressed in *MrgprA3*⁺ neurons (Figure S4). Activated Braf activates MEK, which in turn activates ERK. Consistent with expectations, the percentage of pERK⁺ *MrgprA3*⁺ neurons was significantly increased in *MrgprA3*;Braf mice (10.0% in control *MrgprA3-Cre* mice vs 65.7% in *MrgprA3*;Braf mice, Figure 4A-B). Furthermore, ERK phosphorylation was significantly elevated in the TGs

of *MrgprA3;Braf* mice, compared to *MrgprA3-Cre* mice (Figure 4C-D). Importantly, even though *Braf* activity was increased in *MrgprA3*⁺ neurons of *MrgprA3;Braf* mice, the proportion of other population markers, including CGRP and NF200, were not different between *MrgprA3-Cre* and *MrgprA3;Braf* mice - suggesting that fates of peptidergic (Figure S5A-B) and large-diameter (Figure S5C-D) neurons were preserved in *MrgprA3;Braf* mice. Because GFP fluorescence of the Cre-GFP protein is nearly completely localized to the nucleus in *MrgprA3-Cre* mice, we further generated *MrgprA3;tdTomato* and *MrgprA3;Braf; tdTomato* mice (Figure S4), so that *MrgprA3*⁺ fibers in the skin can be visualized using the red *tdTomato* fluorescent reporter. Imaging showed that the innervation density of *MrgprA3*⁺ sensory fibers was increased by 60% in *MrgprA3;Braf; tdTomato* mice, compared to *MrgprA3;tdTomato* mice (Figure 4E-F, Figure S6).

MrgprA3⁺ neurons from *MrgprA3;Braf* mice show increased excitability

To test if increased pERK signaling in *MrgprA3*⁺ neurons results in enhanced excitability of this population, we performed whole cell patch clamp

recordings of cultured TG neurons from *MrgprA3;tdTomato* and *MrgprA3;Braf; tdTomato* mice. *MrgprA3*⁺ neurons were identified by *tdTomato* fluorescence and recorded in current clamp mode. Each neuron was injected with a train of 200 ms currents, increasing from 0 to 260 pA in 20 pA increments, to evoke action potentials (APs) firing. While *MrgprA3*⁺ neurons from *MrgprA3;tdTomato* mice only generated a few APs, most of which were single spikes, those from *MrgprA3;Braf; tdTomato* mice fired significantly more APs and frequently generated multiple spikes (Figure 5A). Moreover, the minimum current required to evoke AP was significantly lower in *MrgprA3*⁺ neurons from *MrgprA3;Braf; tdTomato* mice than those from control mice (137 ± 11.6 pA in *MrgprA3;tdTomato* mice vs 55 ± 7.3 pA in *MrgprA3;Braf; tdTomato* mice, Figure 5B). Specifically with 140 pA currents, *MrgprA3*⁺ neurons from *MrgprA3;tdTomato* mice produced single spike or no firing, while those from *MrgprA3;Braf; tdTomato* mice generated an average of 3 spikes (Figure 5C-D).

Calcium imaging experiments further confirmed that CQ and capsaicin responsiveness were enhanced in *MrgprA3*⁺ neurons of *MrgprA3;Braf* mice. While the percentage of CQ responsive neurons was not




Figure 3. ERK phosphorylation and *MrgprA3*⁺ skin fiber density are enhanced in CD condition. (A) Immunostaining of pERK in TGs from *MrgprA3-Cre* mice with CD condition (left panel: arrows indicate pERK⁺ neurons; middle panel: arrows indicate *MrgprA3*⁺ neurons; right panel: arrows indicate double positive neurons). (B) Quantification of the proportion of pERK⁺ neurons in TGs from mice with CD condition. (n = 3). (C) Quantification of pERK positivity in *MrgprA3*⁺ TG neurons in mice with CD condition. (D) Immunostaining of *MrgprA3-tdTomato* in control and lesional skin of CD model mice. The thickness of slice is 50 μ m. Above the dotted line is the epidermis. (E) Quantification of *MrgprA3*⁺ fiber density in control and lesional skin of CD model mice. The scale bar represents 25 μ m. *, $P < 0.05$; ***, $P < 0.001$. All data are presented as mean \pm SEM.

changed (Figure 5E), CQ induced calcium amplitudes were significantly increased in *MrgprA3*⁺ neurons from *MrgprA3;Braf* mice, compared with those from the *MrgprA3-Cre* mice (Figure 5F). Importantly, capsaicin induced calcium amplitudes were also significantly increased in *MrgprA3*⁺ neurons from *MrgprA3;Braf* mice (Figure 5G-H).

TRPV1 mediated itch, but not pain, is selectively enhanced in *MrgprA3;Braf* mice

Next, we assessed the consequences of enhanced pERK signaling and excitability of *MrgprA3*⁺ neurons on itch and pain. We first tested if CQ induced acute itch was altered in *MrgprA3;Braf* mice, and found that scratching, but not wiping, was significantly increased compared to control mice (Figure 6A). Selective itch enhancement was also found in the CD model. After SADBE treatments, *MrgprA3;Braf* mice scratched significantly more than control *MrgprA3-Cre* mice (43 ± 5.3 vs 21 ± 3.0 , Figure 6B), while no difference in wiping was found (Figure 6B).

Remarkably, selective itch enhancement was also observed in the *MrgprA3;Braf* mice after capsaicin injection. Capsaicin injection acutely and potently induces burning pain in naïve mice [15]. While capsaicin induced acute pain was not different between *MrgprA3;Braf* and *MrgprA3-Cre* mice, *MrgprA3;Braf* mice scratched in response to the capsaicin injections (28 ± 5.0 *MrgprA3;Braf* vs. 8 ± 1.7 *MrgprA3-Cre* mice, Figure 6C) - indicating that enhanced *MrgprA3*⁺ neuron excitability leads to itch hypersensitivity. This itch response was attenuated by DREADD mediated silencing of *MrgprA3*⁺ neurons. Similar to our findings with the wild-type CD model mice (Figure 2E), capsaicin induced scratching in *MrgprA3;Braf* mice was significantly inhibited by CNO pre-treatment (Figure 6D), without detectible effects on pain responses (Figure 6E). Additional von Frey and Hargreaves assays also did not detect any changes in acute pain responses in the *MrgprA3;Braf* mice (Figure S7A-B).




Figure 4. ERK phosphorylation and *MrgprA3*⁺ skin fiber density are elevated in *MrgprA3;Braf* mice. (A) Immunostaining of pERK in TGs from *MrgprA3-Cre* and *MrgprA3;Braf* mice (top panel: arrows indicate pERK⁺ neurons; middle panel: arrows indicate *MrgprA3*⁺ neurons; bottom panel: arrows indicate double positive neurons). (B) Quantification of pERK positivity in *MrgprA3*⁺ TG neurons from *MrgprA3-Cre* and *MrgprA3;Braf* mice. (C) Representative western blot bands showing pERK, total ERK, and GAPDH loading control in TGs from *MrgprA3-Cre* and *MrgprA3;Braf* mice. (D) Quantification of western blot bands from the previous panel, showing normalized pERK intensity in TGs of *MrgprA3-Cre* and *MrgprA3;Braf* mice. (n = 3). (E) Immunostaining of tdTomato in skin from *MrgprA3;tdTomato* and *MrgprA3;Braf;tdTomato* mice. The thickness of slice is 50 μ m. Above the dotted line is the epidermis. (F) Quantification of *MrgprA3*⁺ fiber density in skin. The scale bars represent 50 μ m. **, $P < 0.01$; ***, $P < 0.001$. All data are presented as mean \pm SEM.




Figure 5. MrgprA3⁺ neurons from MrgprA3;Braf;tdTomato mice show increased excitability. (A) Current induced AP firings in MrgprA3⁺ TG neurons from MrgprA3;tdTomato and MrgprA3;Braf;tdTomato mice. **(B)** Threshold current required to induce the first AP in MrgprA3⁺ TG neurons from MrgprA3;tdTomato and

MrgprA3;Braf;tdTomato mice. (n = 8). (C) Representative 140 pA induced APs in *MrgprA3*⁺ TG neurons from *MrgprA3;tdTomato* and *MrgprA3;Braf;tdTomato* mice. (D) Quantification of the number of 140pA induced APs in *MrgprA3*⁺ TG neurons from *MrgprA3;tdTomato* and *MrgprA3;Braf;tdTomato* mice. (n = 8). (E) The percentage of CQ responsive TG neurons in *MrgprA3-Cre* and *MrgprA3;Braf* mice. (n = 4). (F) CQ induced calcium responses (averaged trace) in TG neurons from *MrgprA3-Cre* and *MrgprA3;Braf* mice. The calcium responses difference between two kinds of mice were compared by the area under the curve. (n = 4). (G) The percentage of capsaicin responsive TG neurons in *MrgprA3-Cre* and *MrgprA3;Braf* mice. (n = 4). (H) Capsaicin induced calcium responses (averaged trace) in TG neurons from *MrgprA3-Cre* and *MrgprA3;Braf* mice. The calcium responses difference between two kinds of mice were compared by the area under the curve. (n = 4). **, $P < 0.01$; ***, $P < 0.001$. All data are presented as mean \pm SEM.




Figure 6. TRPV1 mediated itch, but not pain, is selectively enhanced in *MrgprA3;Braf* mice. (A) CQ (2 mM/20 μ L) induced scratching behavior in *MrgprA3-Cre* and *MrgprA3;Braf* mice. (*, compared with *MrgprA3-Cre* mice; n = 6). (B) Spontaneous scratching and wiping behavior in control and *MrgprA3;Braf* mice with CD condition. (n = 6). (C) Capsaicin (500 μ M/20 μ L) induced scratching and wiping behavior in *MrgprA3-Cre* and *MrgprA3;Braf* mice. (n = 6). (D) Capsaicin (500 μ M/20 μ L) induced scratching behavior in control mCherry AAV injected and hM4Di AAV injected *MrgprA3;Braf* mice after CNO pretreatment. (n = 5). (E) Capsaicin (500 μ M/20 μ L) induced wiping behavior in control mCherry AAV injected and hM4Di AAV injected *MrgprA3;Braf* mice after CNO pretreatment. (n = 5). *, $P < 0.05$; **, $P < 0.01$. All data are presented as mean \pm SEM.

The arachidonic acid metabolite and TRPV1 agonist 20-HETE is enriched in lesional skin of CD model mice

Thus far, our data has demonstrated that pERK signaling is elevated in *MrgprA3*⁺ neurons in CD condition, which leads to increased excitability of *MrgprA3*⁺ neurons and augmented TRPV1 mediated itch. Next, we set to identify endogenous TRPV1 ligands that are produced by lesional CD skin after the third SADBE challenge. To accomplish this, we analyzed skin lysates of CD model mice using UHPLC MS/MS and identified 147 compounds with increased abundance and 153 with decreased abundance in lesional skin, compared to vehicle treated skin (Figure S8 and Figure 7A). Analysis of the 175 compounds with VIP values greater than 1 further showed that the most significant changes were concentrated in phospholipid metabolism pathways (Figure 7B), and that most of the differentially abundant metabolites were associated with glycerophospholipid metabolism (Figure 7C). Among the identified compounds, arachidonic acid metabolites were especially promising candidates as these compounds are components of glycerophospholipids

with broad bioavailability and had been previously implicated in inflammation as well as pain and itch processes. One metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE), had previously been reported to activate TRPV1 [25]. Based on these reasons, we further quantified 20-HETE availability in the skin by UHPLC (Figure 7D-F). Reference 20-HETE compound (Cayman) was used to determine retention time ($t_R = 13.56$ min) and precursor ion ($m/z = 338.34$) in our LC-MS system (Figure 7D and Figure S9A). 20-HETE was found in both control and lesional CD skin (Figure 7E-F and Figure S9B-C). Due to significant thickening of the lesional skin samples, further normalization revealed that the relative concentration of 20-HETE was significantly increased in lesional skin of CD model mice (Figure 7G).

20-HETE mediated TRPV1 activation drives CD-associated itch

Due to the high abundance of 20-HETE in lesional skin of our CD model mice, as revealed by UHPLC, and its potency in activating TG neurons (Figure S10A-F), we next examined if skin derived 20-HETE is a major contributor of TRPV1-mediated itch and pain in CD disorder.




Figure 7. Unbiased metabolomic analysis of lesional skin of CD model mice. (A) Volcano plot highlighting differentially abundant metabolites in lesional CD model skin and control skin comparison, presented as $-\log_{10}(P\text{-value})$ of CD/control. (B) Pathway analysis of differentially abundant compounds. (C) Enrichment analysis of differentially available compounds. (D) UHPLC ion chromatogram of the reference 20-HETE compound. (E-F) Ion chromatograms of 20-HETE in control and lesional CD skin lysates. (G) Normalized 20-HETE abundance in control and lesional CD skin. **, $P < 0.01$. All data are presented as mean \pm SEM.

To accomplish this, wildtype CD model mice were given either vehicle or HET0016 (a selective 20-HETE synthase inhibitor [26]) before each SADBE challenge (Figure 8A). Systemic HET0016 treatment blocked epidermal thickening at the SADBE challenged area (Figure 8B). ELISA assay confirmed that 20-HETE abundance was significantly reduced in the lesional skin of HET0016 treated mice (Figure 8C). Moreover, HET0016 treated mice showed mildly attenuated wiping behavior (68 ± 12.3 vehicle vs. 43 ± 9.6 HET0016) (Figure 8D), but significantly reduced scratching (30 ± 5.1 vehicle vs. 16 ± 3.5 HET0016) (Figure 8E). Finally, to explore if our findings in mice are relevant to human CD pathology, we tested 20-HETE availability in biopsies of healthy control (HC) and lesional CD skin by LC-MS (Figure 8F-I). Consistent with mouse CD model, lesional human CD skin showed significantly elevated 20-HETE abundance and prominent acanthosis, compared to HCs (Figure 8J-K).

Discussion

Pain and itch are two fundamental sensory modalities initiated and mediated by primary sensory neurons. Recent progress has identified the discrete primary sensory neuron populations in the DRG and TG that detect, encode, and transmit pain and itch [6, 27]. Mrgprs and the neurons that express them have been implicated as critical itch sensors, and as drivers of pathological itch that's commonly associated with chronic, inflammatory skin conditions. Primary sensory neurons that express MrgprA3 were recently reported to mediate both itch and pain - metabotropic activation of MrgprA3⁺ neurons evoked itch in mice, while ionotropic activation these neurons using optogenetics or ATP induced aversive responses distinct from scratching [28]. While broad activation of TRPV1, an ion channel, by capsaicin results in burning pain, selective activation of MrgprA3⁺ neurons using capsaicin, in the absence of nociceptive neuron activation, evokes itch [13]. The contribution of MrgprA3⁺ neurons and TRPV1 channels to CD-associated chronic itch and pain, however, is still unclear.

SADBE has been widely used to induce non-allergic and allergic CD in mice, SADBE model faithfully recapitulates skin inflammation and the chronic itch and pain symptoms of human CD, and was selected for studying CD-associated chronic itch and pain [14]. Mrgprs were previously reported to be required for CD-associated itch [29]. Our findings in current study further confirms that MrgprA3⁺ neurons become hypersensitive in CD condition, and drives CD-associated itch and itch hypersensitivity (Figures 2E). It should be noted that manipulation of

MrgprA3⁺ neurons only affected itch related behavior in our CD model, as neither pharmacological activation of this population using CQ or silencing using hM4Di DREADD produced any detectable difference in pain related behaviors in CD model mice. These findings provide a potential mechanism for itch hypersensitivity commonly associated with human CD [30].

Remarkably, we found that capsaicin and TRPV1 actions become itch-biased in CD, leading to itch hypersensitivity. We found that capsaicin induced wiping behavior in both control and CD model mice, but wiping was not increased in CD model mice - suggesting that TRPV1 mediated pain is not changed in CD (Figure 1E). Conversely, capsaicin induced significant scratching in CD model mice, but not control mice, indicating that TRPV1 gains itch initiating functions in CD (Figure 1G).

Further studies using *Mrgprs*^{-/-} mice suggested that, while spontaneous CD-associated itch is diminished by Mrgprs deficiency, capsaicin induced itch in CD model mice is not Mrgprs dependent (Figure 2B). This finding prompted us to instead examine the activity of MrgprA3⁺ neuron. Indeed, capsaicin induced scratching in CD model mice was abolished by DREADD silencing of MrgprA3⁺ neurons (Figure 2E). Our findings demonstrate that while Mrgprs are not required for CD itch hypersensitivity, MrgprA3⁺ neurons are. Additional experiments further showed that ERK phosphorylation was significantly increased in TGs, especially in MrgprA3⁺ neurons, of CD model mice. Previous studies have revealed that increased pERK, an indication of activated MAPK signaling, is related to increased neuronal excitability or stimuli sensitivity, and has been shown to result in the development of spontaneous chronic itch [23]. To test if increased MrgprA3⁺ neuron excitability contributes to CD-associated itch hypersensitivity, we generated *MrgprA3;Braf* mice. In this line, constitutively active Braf is specifically expressed in MrgprA3⁺ neurons, resulting in dramatically elevated ERK phosphorylation in these neurons, increased MrgprA3⁺ neuron fiber density in the skin, and increased MrgprA3⁺ neuron excitability in response to current, CQ, and capsaicin stimulations (Figure 5F, H). *MrgprA3;Braf* mice were also scratched significantly more in response to CQ in the CD model. Importantly, capsaicin also induced scratching in *MrgprA3;Braf* mice, which was blocked by DREADD silencing (Figure 6D). These findings are consistent with the observations from the CD model mice and the notion that MrgprA3⁺ neuron hypersensitivity drives CD-associated allodynia.




Figure 8. 20-HETE mediated TRPV1 activation drives CD-associated itch. (A) Schematic of the SADBE induced CD model and HET0016 administration. (B) Representative H&E staining of lesional skin from CD model mice treated with vehicle or HET0016. (C) Normalized 20-HETE abundance in lesional skin from CD model mice treated with vehicle or HET0016. (D) Spontaneous wiping in CD model mice treated with vehicle or HET0016. (E) Spontaneous scratching in CD model mice treated with vehicle or HET0016. (F-I) UHPLC ion chromatograms and MS spectra of 20-HETE in healthy control and lesional CD human skin. (J) Representative H&E staining of healthy control and lesional CD human skin. (K) Normalized 20-HETE abundance in healthy control and lesional CD human skin. *, $P < 0.05$; ***, $P < 0.001$. The scale bar represents 50 μm . All data are presented as mean \pm SEM.




Figure 9. TRPV1 mediated allodynia in chronic dermatitis requires MrgprA3⁺ neuron hypersensitivity. Chronic dermatitis enhanced the excitability of MrgprA3⁺ neurons (purple traces) and increased the abundance of 20-HETE, an endogenous TRPV1 ligand, resulting in allodynia. Constitutively active Raf, leading to elevated ERK phosphorylation in MrgprA3⁺ neurons (black traces) mimics CD condition itch hypersensitivity.

CD is always accompanied by skin barrier dysfunction and lipid metabolism disorders. The arachidonic acid metabolites 12-hydroperoxyeicosatetraenoic acid (12-HpETE) [31] and 20-HETE [32] had emerged as potential endogenous activators of TRPV1. Our UHPLC and MS confirmed significantly increased 20-HETE abundance in lesional skin of CD model mice and human CD patients (Figure 7G, Figure 8K). Moreover, treatment with HET0016, a potent and selective 20-HETE synthase inhibitor, significantly attenuated 20-HETE availability in CD-like skin, as well as skin inflammation and itch (Figure 8B, C, E).

Together, our study demonstrated that 1. pERK signaling is elevated in itch sensing MrgprA3⁺ neurons in CD condition, leading to hyperactivity of these neurons. And 2. the increased abundance of TRPV1 agonists in lesional CD skin leads to the over-activity of TRPV1 channels in hyperactive MrgprA3⁺ neurons, resulting in TRPV1 mediated allodynia (Figure. 9). Moreover, we demonstrated that silencing MrgprA3⁺ neurons were an effective strategy for itching relief in mouse CD model. Our study elucidated a critical mechanism of CD-associated chronic itch and pain. These findings advanced our understanding CD pathology as well as

sensory biology, and identified novel targets for chronic itch management in clinics.

Abbreviations

TRPV1: Transient Receptor Potential Vanilloid 1; MrgprA3: Mas-related G protein-coupled receptor A3; TG: trigeminal ganglia; DRG: dorsal root ganglia; CD: chronic dermatitis; SADBE: squaric acid dibutylester; CHS: contact hypersensitivity; Aps: action potentials; DREADDs: designer receptors exclusively activated by designer drugs; CNO: clozapine N-oxide.

Supplementary Material

Supplementary figures.

<https://www.thno.org/v14p1615s1.pdf>

Acknowledgements

We thank Equipment Sharing Platform at Basic Medical Experimental Teaching Center, School of Medicine, Nanjing University of Chinese Medicine.

Funding

This project is supported by funding from Jiangsu Provincial Key Research and Development Program (BE2017728), Open Project of Jiangsu

Collaborative Innovation Center of Chinese Medicinal Resources Industrialization (ZDXM-2022-10) and High level key discipline construction project of the National Administration of Traditional Chinese Medicine-Resource Chemistry of Chinese Medicinal Materials (No. zyyzdxx-2023083).

Ethics statement

Human subject was approved by Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (IRB number 2023 [068]); Animal subjects Ethics Committee No. ACU190601.

Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Author contributions

G.Y. designed the study. G.Y., P.L., X.B.H., M.X.Q., and Y.Z. performed experiments. X. L., R.X.S., and C.M.W. analyzed the results. Y.Y., C.Z., F.W., Z.X.T. and J.A.D. provided technical assistance. G.Y. wrote the manuscript. G.Y., Z.X.T. and J.A.D. supervised the entire project.

Competing Interests

The authors have declared that no competing interest exists.

References

- Ma Q. Labeled lines meet and talk: population coding of somatic sensations. *J Clin Invest.* 2010; 120: 3773-8.
- Lamotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. *Nat Rev Neurosci.* 2013; 15: 19-31.
- Baron R, Schwarz K, Kleinert A, Schattschneider J, Wasner G. Histamine-induced itch converts into pain in neuropathic hyperalgesia. *Neuroreport.* 2001; 12: 3475-8.
- Birklein F, Claus D, Riedl B, Neundorfer B, Handwerker HO. Effects of cutaneous histamine application in patients with sympathetic reflex dystrophy. *Muscle Nerve.* 1997; 20: 1389-95.
- Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. *Exp Dermatol.* 1999; 8: 39-45.
- Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. *Pain.* 2006; 126: 16-23.
- Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. *Neurology.* 2004; 62: 212-7.
- Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. *Cell.* 2009; 139: 1353-65.
- Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. *J Neurophysiol.* 2003; 89: 2441-8.
- Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, LaMotte RH, et al. Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. *J Neurosci.* 2007; 27: 7490-7.
- Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. *Sci Signal.* 2011; 4: ra45.
- Liu Q, Sikand P, Ma C, Tang Z, Han L, Li Z, et al. Mechanisms of itch evoked by beta-alanine. *J Neurosci.* 2012; 32: 14532-7.
- Han L, Ma C, Liu Q, Weng H-J, Cui Y, Tang Z, et al. A subpopulation of nociceptors specifically linked to itch. *Nat Neurosci.* 2012; 16: 174-82.
- Luo JL, Feng J, Yu G, Yang P, Mack MR, Du JH, et al. Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch. *J Allergy and Clin Immunol.* 2018; 141: 608-19.
- Yu G, Yang NN, Li FX, Chen MJ, Guo CXJ, Wang CM, et al. Enhanced itch elicited by capsaicin in a chronic itch model. *Mol Pain.* 2016; 12: 1744806916645349.
- Shimada SG, LaMotte RH. Behavioral differentiation between itch and pain in mouse. *Pain.* 2008; 139: 681-7.
- Yan JJ, Ye F, Ju Y, Wang DJ, Chen J, Zhang XY, et al. Cimifugin relieves pruritus in psoriasis by inhibiting TRPV4. *Cell Calcium.* 2021; 97: 102429.
- Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. *Nat Protoc.* 2022; 17: 1735-61.
- García-Campos MA, Espinal-Enríquez J, Hernández-Lemus E. Pathway analysis: state of the art. *Front Physiol.* 2015; 6: 383.
- Hu XQ, Tang Y, Ju Y, Zhang XY, Yan JJ, Wang CM, et al. Scratching damages tight junctions through the Akt-claudin 1 axis in atopic dermatitis. *Clin Exp Dermatol.* 2021; 46: 74-81.
- Granot M, Yakov S, Kuperman P, Yosipovitch G, Ramon M. Catastrophizing thinking towards itch and pain in chronic itch patients. *J Eur Acad Dermatol Venereol.* 2021; 35: e164-e242.
- Qu L, Fan N, Ma C, Wang T, Han L, Fu K, et al. Enhanced excitability of MRGPRA3- and MRGPRD-positive nociceptors in a model of inflammatory itch and pain. *Brain.* 2014; 137: 1039-50.
- Zhao ZQ, Huo FQ, Jeffrey J, Hampton L, Demehri S, Kim S, et al. Chronic itch development in sensory neurons requires BRAF signaling pathways. *J Clin Invest.* 2013; 123: 4769-80.
- Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. *Cell Signal.* 2003; 15: 463-9.
- Hamers A, Primus CP, Whitear C, Kumar NA, Masucci M, Montalvo Moreira SA, et al. 20-hydroxyeicosatetraenoic acid (20-HETE) is a pivotal endogenous ligand for TRPV1-mediated neurogenic inflammation in the skin. *Br J Pharmacol.* 2022; 179: 1450-69.
- Zhao R, Teng X, Yang Y. Calpain as a therapeutic target for hypoxic-ischemic encephalopathy. *Mol Neurobiol.* 2024; 61: 533-40.
- Guo C, Jiang H, Huang CC, Li F, Olson W, Yang W, et al. Pain and itch coding mechanisms of polymodal sensory neurons. *Cell Rep.* 2023; 42: 113316.
- Sharif B, Ase AR, Ribeiro-da-Silva A, Séguela P. Differential coding of itch and pain by a subpopulation of primary afferent neurons. *Neuron.* 2020; 106: 940-51.e4.
- Li FX, Wang CM, Hu DY, Zhang XY, Shen R, Zhou Y, et al. mMrgprA3/mMrgprC11/hMrgprX1: potential therapeutic targets for allergic contact dermatitis-induced pruritus in mice and humans. *Contact Dermatitis.* 2022; 86: 286-94.
- Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. *Am J Clin Dermatol.* 2018; 19: 319-32.
- Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc Natl Acad Sci U S A.* 2000; 97: 6155-60.
- Wen H, Östman J, Bubb KJ, Panayiotou C, Priestley JV, Baker MD, et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. *J Biol Chem.* 2012; 287: 13868-76.